Safety of one eye injection for Stargardt vision loss
Part of Eyes & vision, Genetic & congenital clinical trials.
This study tests a single injection of ASP2020 in the eye to see if it is safe and if it can help improve vision for people with Stargardt disease or similar inherited eye conditions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed diagnosis of Stargardt disease or a related macular dystrophy with genetic testing.
- Your vision must be between 20/500 and 20/40 (moderate to severe vision loss).
- You should have no other serious eye diseases like glaucoma, diabetes-related eye damage, or prior eye surgeries.
- You cannot have uncontrolled health conditions like severe heart disease, autoimmune disease requiring immune-suppressing drugs, or active cancer.
- You must be able to have clear imaging of your eye, and your eye pressure must be 21 mmHg or lower.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests how well ALK-001 is tolerated and whether it can slow or improve vision-related changes in people with Stargardt disease. It mainly looks at safety (tolerability) and signs in the eye over about 24 months.
This study observes how Stargardt disease and similar eye conditions change over time in children and adults. It aims to learn more about the disease progression to help develop future treatments.
This trial tests a new drug, ALK-001, to see if it can slow down vision loss from Stargardt disease. It is for people who have a confirmed genetic diagnosis and are between 8 and 45 years old.
This trial tests a single injection of a new medicine, RTx-021, into the eye for people with Stargardt disease. The goal is to see if it is safe and to find the right dose.
This trial tests a new gene therapy called SB-007 for people with Stargardt disease (STGD1). It is given as an injection under the retina to see if it is safe and can help slow vision loss.
This study tests a new way to measure vision, called MLSDT, in people with normal sight or vision loss from Stargardt disease or geographic atrophy (a type of advanced age-related macular degeneration). Results will help doctors better understand how well patients can see.
Hear when a new Stargardt Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.